Fused compounds that inhibit vanilloid receptor subtype 1 (VR1) receptor
The present invention discloses novel compounds of general formula (I) or a pharmaceutically acceptable salt or prodrug thereof (in which X 1 -X 5 , R 5 -R 8b , Z 1 -Z 2 and Ar 1 are defined herein), a method for inhibiting the VR1 receptor in mammals using these compounds, a method for controlling pain in mammals, and pharmaceutical compositions including those compounds and a process for making those compounds.
1. A method of treating a disorder by inhibiting vanilloid receptor subtype 1 in a mammal, wherein the disorder is selected from the group consisting of pain, bladder overactivity, urinary incontinence, inflammatory pain, osteoarthritic pain, chronic lower pain, and migraine, comprising administering a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt or prodrug thereof
wherein
---is absent;
X 1 is CR 1 ;
X 2 is N or CR 2 ;
X 3 is N, NR 3 , or CR 3 ;
X 4 is a bond;
provided that at least one of X 2 and X 3 is N;
Z 1 is O;
Z 2 is NH;
Ar 1 is selected from the group consisting of
R 1 , R 3 , R 5 , R 6 , and R 7 are each independently selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, R B (SO) 2 R A N—, R A O(SO) 2 —, R B O(SO) 2 —, Z A Z B N—, (Z A Z B N)alkyl, (Z A Z B N)carbonyl, (Z A Z B N)carbonylalkyl, and (Z A Z B N)sulfonyl;
R 2 is selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, carboxy, carboxyalkyl, cyano, cyanoalkyl, cycloalkyl, cycloalkylalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO C—, R B (SO) 2 R A N—, R A O(SO) 2 —, R B O(SO) 2 —, Z A Z B N—, (Z A Z B N)alkyl, (Z A Z B N)alkylcarbonyl, (Z A Z B N)carbonyl, (Z A Z B N)carbonylalkyl, (Z A Z B N)sulfonyl, (Z A Z B N)C(═NH)—, (Z A Z B N)C(═NCN)NH— and (Z A Z B N)C(═NH)NH—;
R 8a is hydrogen or alkyl;
R 8b is absent;
R 9 , R 10 , R 11 , and R 12 are each individually selected from the group consisting of hydrogen, alkenyl, alkoxy, alkoxyalkoxy, alkoxyalkyl, alkoxycarbonyl, alkoxycarbonylalkyl, alkyl, alkylcarbonyl, alkylcarbonylalkyl, alkylcarbonyloxy, alkylthio, alkynyl, aryl, carboxy, carboxyalkyl, cyano, cyanoalkyl, formyl, formylalkyl, haloalkoxy, haloalkyl, haloalkylthio, halogen, heteroaryl, heterocycle, hydroxy, hydroxyalkyl, mercapto, mercaptoalkyl, nitro, (CF 3 ) 2 (HO)C—, R B (SO) 2 R A N—, R A O(SO) 2 —, R B O(SO) 2 —, Z A Z B N—, (Z A Z B N)alkyl, (Z A Z B N)carbonyl, (Z A Z B N)carbonylalkyl, and (Z A Z B N)sulfonyl, wherein Z A and Z B are each independently hydrogen, alkyl, alkylcarbonyl, formyl, aryl, or arylalkyl, provided that at least one of R 9 , R 10 , R 11 , or R 12 is other than hydrogen, or R 10 and R 11 taken together with the atoms to which they are attached form a cycloalkyl, cycloalkenyl, or heterocycle ring;
R 13 is selected from the group consisting of alkyl, aryl, heteroaryl and halogen;
R A is hydrogen or alkyl; and
R B is alkyl, aryl, or arylalkyl.
2. The method according to claim 1 wherein the disorder is pain.
3. The method according to claim 1 wherein the disorder is bladder overactivity.
4. The method according to claim 1 wherein the disorder is urinary incontinence.
5. The method according to claim 1 wherein the disorder is inflammatory pain.
6. The method according to claim 1 wherein the disorder is osteoarthritic pain.
7. The method according to claim 1 wherein the disorder is chronic lower pain.
8. The method according to claim 1 wherein the disorder is migraine.